Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

Abstract Background Endocrine therapy is recommended as a first-line treatment for hormone receptor-positive metastatic breast cancer (HR+MBC) patients. No biomarker has been validated to predict tumor progression in that setting. We aimed to prospectively compare the risk of early progression accor...

Full description

Bibliographic Details
Main Authors: Florian Clatot, Anne Perdrix, Ludivine Beaussire, Justine Lequesne, Christelle Lévy, George Emile, Michael Bubenheim, Sigrid Lacaille, Céline Calbrix, Laetitia Augusto, Cécile Guillemet, Cristina Alexandru, Maxime Fontanilles, David Sefrioui, Lucie Burel, Sabine Guénot, Doriane Richard, Nasrin Sarafan-Vasseur, Frédéric Di Fiore
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Breast Cancer Research
Subjects:
ESR1 mutation
Breast cancer
Circulating DNA
CA-15.3
Cell-free DNA
Aromatase inhibitor
Online Access:http://link.springer.com/article/10.1186/s13058-020-01290-x

Internet

http://link.springer.com/article/10.1186/s13058-020-01290-x

Similar Items